Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
10x Genomics, Inc. reports developments in single cell and spatial biology, including financial results, product launches and collaborations tied to its research platforms. The company sells integrated instruments, consumables and software used by academic, translational and biopharmaceutical researchers to analyze biological systems at single-cell and spatial resolution.
Recurring updates cover platforms such as Chromium, Visium, Xenium and Atera; consumables demand; spatial whole-transcriptome analysis; research collaborations and data-generation initiatives; conference presentations; and management commentary on revenue, cash resources and outlook. Company news also reflects applications in oncology, immunology, neuroscience and other disease research areas.
10x Genomics (Nasdaq: TXG) will participate in the upcoming UBS Genomics 2.0 and Medtech Innovations Virtual Summit on August 12, 2020, at 8:00 a.m. PT / 11:00 a.m. ET. The management team will engage in a fireside chat, which can be accessed via a live and archived webcast on the company’s investor website.
10x Genomics is dedicated to advancing human health through its innovative life science technologies, which include instruments, consumables, and software for biological analysis. Their solutions are widely adopted in top research institutions and pharmaceutical companies.
10x Genomics (TXG) announces the launch of its Chromium Single Cell Immune Profiling v2, enhancing research in immunology, oncology, and infectious diseases, including COVID-19. This product improves gene detection sensitivity by up to 60%, enabling researchers to profile thousands of genes at single-cell resolution cost-effectively. Key features include characterizing immune cell diversity and analyzing disease progression. The product is available for pre-order, with shipping expected by month's end.
10x Genomics (TXG) will report its Q2 2020 financial results on August 11, 2020, after market close. A conference call will take place at 1:30 p.m. PT to discuss the results and company outlook. The webcast will be accessible via the company's website and archived for 45 days. 10x Genomics specializes in life science technology, offering integrated solutions that analyze biological systems. The company has been widely adopted by leading research institutions and pharmaceutical companies, with over 740 patents in its portfolio.
10x Genomics (Nasdaq: TXG) has launched its Visium Clinical Translational Research Network (CTRN), selecting 45 members from 185 applications. This initiative aims to enhance research in oncology, immuno-oncology, and other fields by improving workflows in clinical translational research. Members will gain access to a collaborative community, significant discounts, and specialized support related to the Visium platform. The network connects researchers across 39 global institutions, promoting advancements in studies such as tumor response and spatial gene expression.
10x Genomics (TXG) reported a revenue of $71.9 million for Q1 2020, marking a 34% increase from Q1 2019. The company noted a gross margin of 79%, an improvement from 74% the previous year, due to lower accrued royalties. However, operating expenses rose by 80% to $76.7 million, leading to an operating loss of $19.9 million, compared to $3.0 million in the same quarter last year. Notably, 10x Genomics withdrew its 2020 revenue guidance due to uncertainties tied to the COVID-19 pandemic.
10x Genomics (Nasdaq: TXG) will participate in the BofA Securities Virtual Healthcare Conference on May 13, 2020, at 8:00 a.m. Pacific Time. A live and archived webcast will be available on the company’s Investors section of their website.
The company specializes in life science technologies, producing solutions for understanding biology to improve health. Their products are widely used by top global research institutions and pharmaceutical companies, featuring over 700 patents and cited in over 700 research papers.